No Data
FDA to Speed up AI Rollout to Accelerate Drug Reviews
GSK Met Main Goal in Liver Disease Treatment Trial
EU Regulator Finds Suicidal Thoughts as a Side Effect of Hair Loss Therapy
GSK Announced Results From GLISTEN Phase 3 Trial Of Linerixibat In Adults With Cholestatic Pruritus And PBC, A Rare Autoimmune Liver Disease. The Full Data Were Presented In A Late-breaker Oral Presentation At The EASL Congress 2025
GLISTEN Phase III Trial Results Show Linerixibat Significantly Improves Cholestatic Pruritus (Relentless Itch) in Primary Biliary Cholangitis (PBC)
Daily short sale tracking: Palantir's short volume increased by 10 million, with a short sale ratio of 12%
frankinglily : GSK's specialty growth sounds promising.![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
Shaaaw : Mixed analyst ratings have me cautious.